Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer

This review has been withdrawn.

The reason for withdrawal and previous versions are archived and accessible within the withdrawn record in the Cochrane Library.

Health topics:

Cancer > Prostate

Urology > Cancer > Prostate cancer

Published:

13 November 2014

Authors:

Perletti G, Magri V, Marras E, Monti E, Rennie PS, Trinchieri A

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
Perletti G, Magri V, Marras E, Monti E, Rennie PS, Trinchieri A. Second-line, post-docetaxel therapy for advanced, androgen deprivation-refractory prostate cancer. Cochrane Database of Systematic Reviews 2014, Issue 11. Art. No.: CD009998. DOI: 10.1002/14651858.CD009998.pub2